JPMorgan analyst Brian Cheng reiterated an Overweight rating and $66.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst comments "PTGX ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE